Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre
Loading...
Embargo End Date
ICR Authors
Authors
Liu, WK
Patel, R
Crawford, R
Ayres, B
Watkin, N
Tree, A
Pickering, L
Patel, HRH
Ashfar, M
Patel, R
Crawford, R
Ayres, B
Watkin, N
Tree, A
Pickering, L
Patel, HRH
Ashfar, M
Document Type
Journal Article
Date
2021-06-22
Date Accepted
2021-06-22
Abstract
<jats:sec><jats:title>Objective:</jats:title><jats:p> This study aimed to provide real-world data on the multidisciplinary management of metastatic penile squamous-cell carcinoma (mpSCC) patients and their survival outcomes, particularly those who receive best supportive care (BSC). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> A retrospective analysis of 1720 patients, managed via a supra-regional penile-specialist multidisciplinary team was conducted between January 2006 and May 2020. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 101 patients (median age 63 years; interquartile range 56–72 years; 73% ECOG 0/1) were included. Of these, 32% (32/101) had previously received adjuvant chemotherapy prior to metastatic recurrence, 58% (59/101) received chemotherapy and 42% (42/101) received BSC. Further, 17% (17/101) received second-line systemic therapy, and 3% (3/101) received third-line systemic therapy. For first-line systemic-therapy, there was a 46% (27/59) clinical benefit rate (CBR), with 9% (5/59) complete response, 15% (9/59) partial response and 22% (13/59) stable disease. Patients receiving second-line therapy ( n=17) had a 29% (5/17) CBR. Median progression-free survival for first- and second-line treatment was 3.2 and 2.2 months, respectively. Median overall survival (mOS) for all patients was 6.2 months. mOS for first-line chemotherapy, second-line chemotherapy and BSC patients was 7.2, 4.5 and 2.0 months, respectively. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> First-line platinum-based chemotherapy is associated with notable response rates in mpSCC patients. Agents with better response rates are needed urgently potentially in combination with platinum-based chemotherapy. </jats:p></jats:sec><jats:sec><jats:title>Level of evidence:</jats:title><jats:p> Level 2b. </jats:p></jats:sec>
Citation
JOURNAL OF CLINICAL UROLOGY, 2021, pp. ? - ? (10)
Source Title
Publisher
SAGE PUBLICATIONS LTD
ISSN
2051-4158
eISSN
2051-4166